Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.

Investigational new drugs - 1 Oct 2016

Pezzani Raffaele, Rubin Beatrice, Bertazza Loris, Redaelli Marco, Barollo Susi, Monticelli Halenya, Baldini Enke, Mian Caterina, Mucignat Carla, Scaroni Carla, Mantero Franco, Ulisse Salvatore, Iacobone Maurizio, Boscaro Marco

Abstract excerpt

New therapeutic targets are needed to fight cancer. Aurora kinases (AK) were recently identified as vital key regulators of cell mitosis and have consequently been investigated as therapeutic targets in preclinical and clinical studies. Aurora kinase inhibitors (AKI) have been studied in many cancer types, but their potential capacity to limit or delay metastases has rarely been considered, and never in adrenal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Neoplasms
Share to Adrenocortical Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aurora Kinases

Share to Cell Cycle

Share to Cell Survival

Share to Piperazines

Share to Protein Kinase Inhibitors

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 27177645
DOI: 10.1007/s10637-016-0358-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.PMID 27177645Read ↗

A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeuticsSemantic proximity Read ↗

Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.Semantic proximity Read ↗

Solid Cancer Treatment With Aurora Kinase Inhibitors: Towards a Personalized Medicine.Semantic proximity Read ↗

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.Semantic proximity Read ↗

Updating ACC preclinical models: characterization of two new patient-derived cell linesSemantic proximity Read ↗

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma CellsSemantic proximity Read ↗

Preclinical validation of Aurora kinases-targeting drugs in osteosarcomaSemantic proximity Read ↗

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerSemantic proximity Read ↗

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell linesSemantic proximity Read ↗

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.Semantic proximity Read ↗

Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma TreatmentSemantic proximity Read ↗

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.